170 related articles for article (PubMed ID: 28623406)
1. Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin.
Qu C; Xu L; Yin Y; Peppelenbosch MP; Pan Q; Wang W
Arch Virol; 2017 Oct; 162(10):2989-2996. PubMed ID: 28623406
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine.
Rocha-Pereira J; Jochmans D; Dallmeier K; Leyssen P; Cunha R; Costa I; Nascimento MS; Neyts J
Biochem Biophys Res Commun; 2012 Nov; 427(4):796-800. PubMed ID: 23063849
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.
Coelmont L; Paeshuyse J; Windisch MP; De Clercq E; Bartenschlager R; Neyts J
Antimicrob Agents Chemother; 2006 Oct; 50(10):3444-6. PubMed ID: 17005827
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.
Wang Y; Zhou X; Debing Y; Chen K; Van Der Laan LJ; Neyts J; Janssen HL; Metselaar HJ; Peppelenbosch MP; Pan Q
Gastroenterology; 2014 Jun; 146(7):1775-83. PubMed ID: 24582714
[TBL] [Abstract][Full Text] [Related]
5. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication.
Debing Y; Winton J; Neyts J; Dallmeier K
Antiviral Res; 2013 Oct; 100(1):98-101. PubMed ID: 23916729
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the activity of 2'-C-methylcytidine against dengue virus replication.
Lee JC; Tseng CK; Wu YH; Kaushik-Basu N; Lin CK; Chen WC; Wu HN
Antiviral Res; 2015 Apr; 116():1-9. PubMed ID: 25614455
[TBL] [Abstract][Full Text] [Related]
8. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.
Nishiyama T; Kobayashi T; Jirintai S; Nagashima S; Primadharsini PP; Nishizawa T; Okamoto H
Antiviral Res; 2019 Oct; 170():104570. PubMed ID: 31362004
[TBL] [Abstract][Full Text] [Related]
9. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.
Wang Y; Wang W; Xu L; Zhou X; Shokrollahi E; Felczak K; van der Laan LJ; Pankiewicz KW; Sprengers D; Raat NJ; Metselaar HJ; Peppelenbosch MP; Pan Q
Antimicrob Agents Chemother; 2016 May; 60(5):2834-48. PubMed ID: 26926637
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs.
Mihalik KB; Feigelstock DA
PLoS One; 2013; 8(9):e74027. PubMed ID: 24040153
[TBL] [Abstract][Full Text] [Related]
11. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
Todt D; Moeller N; Praditya D; Kinast V; Friesland M; Engelmann M; Verhoye L; Sayed IM; Behrendt P; Dao Thi VL; Meuleman P; Steinmann E
Antiviral Res; 2018 Sep; 157():151-158. PubMed ID: 30036559
[TBL] [Abstract][Full Text] [Related]
12. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
[TBL] [Abstract][Full Text] [Related]
13. In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks.
Osiceanu AM; Murao LE; Kollanur D; Swinnen J; De Vleeschauwer AR; Lefebvre DJ; De Clercq K; Neyts J; Goris N
Antiviral Res; 2014 May; 105():59-63. PubMed ID: 24583031
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target.
Qu C; Zhang S; Wang W; Li M; Wang Y; van der Heijde-Mulder M; Shokrollahi E; Hakim MS; Raat NJH; Peppelenbosch MP; Pan Q
FASEB J; 2019 Jan; 33(1):1008-1019. PubMed ID: 30070932
[TBL] [Abstract][Full Text] [Related]
15. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.
Wang W; Wang Y; Debing Y; Zhou X; Yin Y; Xu L; Herrera Carrillo E; Brandsma JH; Poot RA; Berkhout B; Neyts J; Peppelenbosch MP; Pan Q
Antiviral Res; 2017 Apr; 140():1-12. PubMed ID: 28077314
[TBL] [Abstract][Full Text] [Related]
16. The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model.
Rocha-Pereira J; Jochmans D; Debing Y; Verbeken E; Nascimento MS; Neyts J
J Virol; 2013 Nov; 87(21):11798-805. PubMed ID: 23986582
[TBL] [Abstract][Full Text] [Related]
17. Generation of a Bactrian camel hepatitis E virus by a reverse genetics system.
Zhang W; Ami Y; Suzaki Y; Doan YH; Takeda N; Muramatsu M; Li TC
J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34242156
[TBL] [Abstract][Full Text] [Related]
18. [Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment].
Wawrzynowicz-Syczewska M
Przegl Epidemiol; 2002; 56 Suppl 5():35-40. PubMed ID: 15553070
[TBL] [Abstract][Full Text] [Related]
19. Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation.
Li Y; Li P; Li Y; Zhang R; Yu P; Ma Z; Kainov DE; de Man RA; Peppelenbosch MP; Pan Q
Antiviral Res; 2020 Dec; 184():104967. PubMed ID: 33137361
[TBL] [Abstract][Full Text] [Related]
20. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon.
Debing Y; Emerson SU; Wang Y; Pan Q; Balzarini J; Dallmeier K; Neyts J
Antimicrob Agents Chemother; 2014; 58(1):267-73. PubMed ID: 24145541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
